This excerpt from the Q1 2022 report by Deep Pharma Intelligence highlights how Genomenon’s AI-driven approach identified 3.7x more evidence-supported, pathogenic/likely pathogenic variants.

This excerpt from the Q1 2022 report by Deep Pharma Intelligence highlights how Genomenon’s AI-driven approach identified 3.7x more evidence-supported, pathogenic/likely pathogenic variants.
